Month: July 2024

GREENVILLE, S.C., July 26, 2024 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NASDAQ: UCBI; UCBIO) (the “Company” or “United”) announced today that the Company will transfer the listing of its common stock and its Depositary Shares (each representing 1/1000th interest in a share of Series I Non-Cumulative Preferred Stock) from the Nasdaq Stock Market LLC (“Nasdaq”) to the New York Stock Exchange (“NYSE”). The Company expects to commence trading as a NYSE-listed company upon market open on August 6, 2024. United’s common stock and depositary shares will trade under new ticker symbols, “UCB” and “UCB PRI”, respectively, after the transfer. The Company’s common stock and depositary shares will continue to trade on Nasdaq until the close of the market on August 5, 2024. “We are excited to announce our partnership with NYSE,” said United CEO, Lynn...

RENO, Nev., July 26, 2024 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), maker of Battle Born Batteries® and an industry leader in energy storage, today announced that the Company will release its financial and operational results for the second quarter ended June 30, 2024 after market close on Wednesday, August 14, 2024. The earnings press release will be followed by a conference call on August 14, 2024 at 5:00 PM Eastern Time.   Interested investors and other parties may access the live webcast via the link found here or through the Events and Presentations page within the Investor Relations section of Dragonfly Energy’s website at https://investors.dragonflyenergy.com/events-and-presentations/default.aspx. The call can also be accessed live via telephone by dialing (800)...

TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD).1 “We are extremely disappointed by the CHMP’s negative opinion and understand that this may also be disappointing for the wider Alzheimer’s disease (AD) community. AD is an irreversible, neurodegenerative disease...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that, on behalf of its affiliated and third-party insurance clients and other investors, it has provided a $700 million capital solution to Sony Music Group, an affiliate of Sony Group Corporation (“Sony”), for investments in the music industry. “We are pleased to provide a bespoke capital solution to an affiliate of one of the world’s leading companies. This investment allows our clients to invest in high grade securities while helping Sony to execute its business plans,” said Apollo Partner Jamshid Ehsani. About Apollo Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus...

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ:SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, will report financial results for the second quarter 2024 on Tuesday, August 6, 2024, before the U.S. stock market opens. Management will discuss the results on a webcast at 8:30 a.m. ET. The live webcast and replay can be accessed at https://investors.vividseats.com/. About Vivid Seats Founded in 2001, Vivid Seats is a leading online ticket marketplace committed to becoming the ultimate partner for connecting fans to the live events, artists, and teams they love. Based on the belief that everyone should “Experience It Live,” the Chicago-based company provides exceptional...

TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Chemomab had previously announced on November 6, 2023, that it was notified by Nasdaq that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s American Depositary Shares (“ADSs”) had been below $1.00 for more than 30 consecutive...